NCT01582503

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 578 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	MEMP1972A	Subcutaneous repeating dose
DRUG	MEMP1972A	Subcutaneous repeating dose
DRUG	MEMP1972A	Subcutaneous repeating dose
DRUG	placebo	Subcutaneous repeating dose

Timeline

• Start date: 2012-04-01
• Primary completion: 2014-05-01
• Completion: 2014-11-01
• First posted: 2012-04-20
• Last updated: 2016-11-02

Locations

145 sites across 14 countries: United States, Argentina, Belgium, Bulgaria, Canada, Germany, Hungary, Mexico, New Zealand, Peru, Poland, Romania, Russia, Ukraine